{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-23-000109","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.095682+00:00","generated_at":"2026-06-10T14:22:08.747582+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Exelixis finalizes separation with former CMO Vicki Goodman, consulting through Dec 2023","bullets":["Dr. Goodman concluded service as EVP Product Development & CMO effective August 23, 2023.","Separation agreement provides severance payments and benefits under company's Change in Control and Severance Benefit Plan, payable in lump sum.","Consulting agreement for up to 4 months (Sept 1 to Dec 31, 2023) with monthly fee of $20,000.","Consulting may be terminated by either party with 5 business days' notice."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-23-000109","json":"https://secwatch.observer/filing/0000939767-23-000109.json","markdown":"https://secwatch.observer/filing/0000939767-23-000109.md","text":"https://secwatch.observer/filing/0000939767-23-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/0000939767-23-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/exel-20230913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:22:08.747582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb00eaf6c1","claim":"Vicki L. Goodman departed as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer at EXELIXIS, INC..","evidence_excerpt":"Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of the Company, effective as of August 23, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000109/0000939767-23-000109-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"concluded"},{"label":"Role","value":"Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}